Open AccessAn International, Randomized, Double-Blind, Placebo-Controlled, Study of Valacyclovir for the Suppression of Herpes Simplex Virus Type 2 Genital Herpes in Newly Diagnosed Patients
Author(s) -
Kenneth H. Fife,
Terri Warren,
Scott E. Justus,
Catherine K. Heitman
Publication year - 2008
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/olq.0b013e31816d1f42
Subject(s) - medicine , placebo , herpes genitalis , herpes simplex virus , genital herpes , valaciclovir , sex organ , viral shedding , adverse effect , sexually transmitted disease , genital warts , viral disease , herpesviridae , immunology , virus , pathology , syphilis , human immunodeficiency virus (hiv) , alternative medicine , cervical cancer , biology , genetics , cancer
Antiviral suppressive therapy of genital herpes is often initiated based on the established pattern of recurrences in an individual. Because most persons with first episode herpes simplex virus type 2 (HSV-2) infection experience recurrences and because viral shedding occurs frequently in the first year after infection, we examined the strategy of initiating suppressive therapy shortly after diagnosis of genital HSV-2 infection.